The FDA recently granted approval for Simtriyo, a new treatment for ADHD developed by the Japanese pharmaceutical company Otsuka. This medication marks the first and only ADHD treatment categorized as an NDSRI, or norepinephrine, dopamine and serotonin reuptake inhibitor. By targeting these three neurotransmitters simultaneously, the drug aims to support attention and behavioral regulation in both adults and children who weigh at least 20 kilograms.
The clinical foundation for this approval includes four Phase 3 trials involving more than 800 adults, as well as separate studies for children and adolescents. Results showed statistically significant improvements in ADHD symptoms, with many patients reporting noticeable changes within the first week of treatment. While common side effects such as reduced appetite, headache, and nausea were reported, researchers described the overall safety profile as favorable.
Experts note that ADHD treatment is often a trial of various options due to the different ways the condition manifests in individuals. Dr. Lenard Adler of NYU Langone Health stated that the introduction of a new mechanism of action provides important alternatives for patients who may not respond well to traditional stimulants or who experience intolerable side effects from existing options. The medication is currently awaiting a final controlled substance classification from the DEA, which is expected to conclude in the coming months.
While the drug is initially heading to the U.S. market, medical professionals globally are watching the release closely. Because Simtriyo functions differently than current options like atomoxetine, it represents a shift in how clinicians approach patient care. Pharmaceutical analysts suggest this launch will expand the range of available therapies, potentially creating a new category for those who have exhausted traditional stimulant-based approaches.